Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

T. Rowe Price Health Sciences Fund (PRHSX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research- development- production- or distribution of products or services related to health care- medicine- or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size- the majority of fund assets are expected to be invested in large- and mid-capitalization companies.


1 month+2.69% 3 years+9.40%
3 months+2.04% 5 years+20.89%
1 year+26.92% Since inception+14.72%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+20.89%+16.79%
Expense ratio0.77%1.33%
Risk 5 year sharpe ratio1.331.12
Net assets$11.9B$3.1B
Average market cap$25.2B$27.3B
Average P/E25.822.4
Portfolio turnover25%25%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyT. Rowe Price
Fund manager & tenureZiad Bakri / 1 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock94.11%
International stock5.09%
Fixed income0.16%
Top 5 Sectors
Portfolio weighting
Healthcare 93.76%
Industrial materials 0.91%
Consumer service 0.89%
Financial service 0.38%
Telecommunication 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth6.06%
BDX Becton Dickinson and Co3.96%
ISRG Intuitive Surgical3.95%
VRTX Vertex Pharmaceuticals Inc3.15%
CI Cigna Corp3.00%
ALXN Alexion Pharmaceuticals Inc2.89%
AGN Allergan2.48%
PBYI Puma Biotechnology Inc2.28%
BIIB Biogen2.22%
A Agilent Technologies Inc2.18%